Excellent Response to Therapeutic Plasma Exchange in Myasthenia Gravis Patients with or Without Autoantibodies
A study out of the University of Texas Southwestern Medical Center found a 96 percent response rate to treatment with therapeutic plasma exchange (PLEX) in a series of 58 consecutive myasthenia gravis (MG) patients, with no significant difference in response between those with or without autoantibodies.
Novo Nordisk’s Esperoct Approved to Treat Individuals with Hemophilia A
FDA approved Esperoct (antihemophilic factor[recombinant], glycopegylatedexei), an extended half-life factor VIII molecule for replacement therapy in people with hemophilia A.
First Therapy Approved to Treat Rare Blood Clotting Disorder
FDA has approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive
therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura.
FDA Approves Hepatitis A and Measles Exposure Drug
FDA has approved Grifols’ GamaSTAN to treat people exposed to measles and the hepatitis A viruses.
Subcutaneous Lanadelumab Treatment Reduces Attack Rate in Patients with Hereditary Angioedema
Subcutaneous administration of lanadelumab, an investigational monoclonal antibody intended for the prevention of attacks in patients with type I or II hereditary angioedema (HAE), significantly reduced the mean number of attacks compared to placebo treatment.
Human Albumin as Drug Therapy for Decompensated Cirrhosis: A New Lifesaving Role for an Old Player?
A growing body of evidence suggests known pharmacologic properties of human albumin may contribute to reducing the risk of a range of cirrhosis complications, including bacterial sepsis, irreversible renal injury and death.
New Hemophilia A Treatment Approved by FDA
The U.S. Food and Drug Administration (FDA) has approved Bayer’s Jivi (BAY94-9027) as a preventive treatment for bleeding in hemophilia A.
Neonatal Fc Receptor Antagonist Efgartigimod Sustainably Reduces Circulating IgG Level in Humans
Investigators from the Belgian biotechnology company argenx and U.S. collaborators conducted a PhaseI clinical study to assess a novel modified antibody Fc fragment (efgartigimod) that reduces the circulating IgG level by blocking neonatal Fc receptor-mediated IgG recycling.
The Growing Threat of Antibiotic-Resistant Illnesses
A host of programs continue to be implemented in the United States and globally to address antibiotic-resistant illnesses.
Cinryze Approved for Preventing Pediatric Angioedema Attacks
The U.S. Food and Drug Administration (FDA) has approved Shire’s Cinryze (C1 esterase inhibitor [human]) to prevent angioedema attacks in children 6 years and older with hereditary angioedema.